High-concentration blue copper peptide and active peptide sustained and controlled release composition and preparation method thereof

Abstract

The invention relates to a high-concentration blue-copper peptide and active peptide sustained and controlled release composition, which comprises poloxamer, blue-copper peptide, fat-soluble polypeptide and water-soluble polypeptide. The fat-soluble polypeptide is prepared from the following components: palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4 and the like, and the water-soluble polypeptide is prepared from the following components: blue copper peptide, poloxamer, acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine and snake venom-like tripeptide. According to the high-concentration blue copper peptide and active peptide sustained and controlled release composition and the preparation method thereof disclosed by the invention, the composition is converted into a semi-solid state at body temperature, so that the blue copper peptide and various active peptides are slowly and continuously released. In vitro animal and human body experiments assess the recovery rate, slow release process, and efficacy of the composition in skin condition improvement.

Description

Technical Field

[0001] The invention relates to the technical field of cosmetics, and in particular to a formula combination with a sustained-release effect and containing high-concentration blue copper peptide and other skin active substances based on poloxamer thermosensitive gel. Background Art

[0002] Blue copper peptide (tripeptide-1 copper), with a structural sequence of glycyl-L-histidyl-L-lysine-Cu (Ⅱ), is a complex of metal copper ions and tripeptides, and is the earliest discovered polypeptide with cosmetic effects. As a powerful skin regenerator, its application in the field of anti-aging and wound healing has received great attention. As a bioactive peptide, it has been proven to stimulate the synthesis of collagen and elastin in the skin, promote angiogenesis, improve blood supply to the skin, thereby enhancing the skin's self-repair ability and antioxidant capacity, and combating free radical damage. This is essential for maintaining skin elasticity and reducing fine lines and wrinkles. Many in vitro experiments have shown that blue copper peptides can induce fibroblasts to produce collagen and promote the production of elastin. Blue copper peptides are very effective in treating wounds and skin injuries, not only reducing scar tissue formation, but also stimulating the skin to heal itself.

[0003] In terms of wrinkle removal, blue copper peptide can minimize daily skin damage and delay aging. Although blue copper peptide has many outstanding effects, it is difficult to prepare products containing high concentrations of blue copper peptide due to its incompatibility with thickening materials commonly used in many cosmetics. When added to cosmetics, it is also easily affected by temperature, pH and other factors, causing denaturation and inactivation, making it difficult to exert its unique effects. Traditional delivery systems often fail to effectively allow blue copper peptides to be absorbed by cells, and are easily degraded by the enzyme system in the body, limiting the potential effects of blue copper peptides.

[0004] However, in the application of blue copper peptide, the problem of slow and continuous release at the site of use has not been well solved; and in the process of using blue copper peptide in combination with other components, due to the different peak concentrations of each component, the release time and degree of the active ingredient cannot be well controlled, resulting in each component not being able to exert its own positive effects.

[0005] As a smart material, poloxamer temperature-sensitive gel can respond to slight temperature changes and adjust the drug release rate. Its gel temperature shows a good linear relationship with the concentration of poloxamer in the solution. In the patent with application number CN202210807905.4, a temperature-sensitive gel mask liquid and its preparation method are disclosed, including components such as skin conditioners, modified poloxamer, moisturizers, fragrances and solvents; wherein, the preparation method of the modified poloxamer is: first add poloxamer to toluene, stir and mix, and obtain a mixed solution A; add an acid binding agent to the mixed solution A, add methacryloyl chloride during stirring, stir and mix, stand, cool, and filter to remove the precipitate to obtain a mixed solution B; add the mixed solution B to the n-hexane solution, stir, stand, filter and discard the filtrate to obtain a modified poloxamer. However, only the gel properties of poloxamer are used to shorten the gel time of the mask liquid and improve the casting problem of the mask liquid, and the release rate is not accurately controlled. Moreover, the modified raw materials have not been approved by the US FDA, so their application in the human body is not absolutely safe and reliable.

[0006] In the patent application number CN202210927243.4, a blue copper peptide solution with a penetration-promoting system and its preparation method and application are disclosed. The preparation method comprises the steps of: providing a blue copper peptide solution; providing a penetration-promoting system, wherein the penetration-promoting system comprises an ionic liquid, or the penetration-promoting system comprises an ionic liquid and 4-hydroxyethylpiperazineethanesulfonic acid; adding the penetration-promoting system to the blue copper peptide solution to obtain a blue copper peptide solution with a penetration-promoting system. The ionic liquid used is a carrier to encapsulate the blue copper peptide, and the blue copper peptide is delivered to the effective part of the skin to achieve the effect of giving full play to its efficacy. The present invention can also introduce 4-hydroxyethylpiperazineethanesulfonic acid into the penetration-promoting system, use HEPES to loosen the stratum corneum, and use ionic liquid as a carrier to encapsulate the blue copper peptide, and deliver the blue copper peptide to the effective part of the skin to give full play to its efficacy. HEPES and ionic liquids are commonly used ingredients in cosmetics. While promoting the absorption of blue copper peptides, they can also protect the structure of blue copper peptides and play a synergistic role; however, this method does not have the effect of sustained and controlled release, and thus cannot ensure that the blue copper peptide is not degraded by the enzyme system in the body. Summary of the invention

[0007] In order to overcome the shortcomings of the background technology, the present invention discloses a high-concentration blue copper peptide and active peptide sustained-release composition and a preparation method thereof, wherein the composition is liquid at low temperature and turns into a gel semi-solid at body temperature, thereby achieving slow and continuous drug release. Through in vitro animal and human experiments, the recovery rate of the composition, the sustained-release process, and the efficacy in skin regeneration of the composition are evaluated.

[0008] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical scheme:

[0009] A high-concentration blue copper peptide and active peptide sustained-release composition, poloxamer, blue copper peptide, fat-soluble peptide and water-soluble peptide. The fat-soluble peptide includes components such as palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4; the water-soluble peptide includes the following components: blue copper peptide, poloxamer, acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine, and snake venom-like tripeptide.

[0010] In order to further improve the technical solution, the mass fraction of poloxamer of the present invention is 12-25%. The mass concentration of blue copper peptide is 8000-12000ppm. The mass concentration of acetyl hexapeptide-8 is 50-150ppm, the mass concentration of acetyl tetrapeptide-5 is 50-150ppm, the mass concentration of decarboxylated carnosine is 1000-1200ppm, the mass concentration of snake venom tripeptide is 200-300ppm, the mass concentration of palmitoyl tetrapeptide-7 is 10-20ppm; the mass concentration of palmitoyl pentapeptide-4 is 10-20ppm.

[0011] In order to further improve the technical solution, the palmitoyl pentapeptide-4 described in the present invention can also be replaced by one or more of palmitoyl dipeptide-7, tripeptide-3 or acetyl tetrapeptide-11.

[0012] In order to further improve the technical solution, the component range of the blue copper peptide sustained-release composition of the present invention is: the mass fraction of the poloxamer is 12.5%. The mass concentration of the blue copper peptide is 10000ppm, the mass concentration of acetyl hexapeptide-8 is 100ppm, the mass concentration of acetyl tetrapeptide-5 is 100ppm, the mass concentration of decarboxylated carnosine is 1100ppm, the mass concentration of snake venom tripeptide is 250ppm, the mass concentration of palmitoyl tetrapeptide-7 is 15ppm, and the mass concentration of palmitoyl pentapeptide-4 is 15ppm.

[0013] A method for preparing a high-concentration blue copper peptide and active peptide sustained-release composition, the preparation steps of which are as follows: weighing poloxamer with a mass fraction of 12-25%, adding an aqueous solvent, placing it in a refrigerated state at about 5 degrees Celsius until it is completely dissolved, preparing a 30% poloxamer stock solution, then dissolving palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4 in the poloxamer stock solution to prepare a primary mixed solution; then taking another aqueous phase to dissolve water-soluble polypeptides acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine, snake venom-like tripeptide and blue copper peptide, and diluting them to the mass concentration mentioned above, and adding them to the primary mixed solution in a refrigerated state at about 5 degrees Celsius to prepare a sustained-release composition.

[0014] Application of a high-concentration blue copper peptide and active peptide sustained-release composition in facial masks / skin lotions / creams.

[0015] Due to the adoption of the technical scheme as described above, the present invention has the following beneficial effects: the present invention discloses a high-concentration blue copper peptide and an active peptide sustained-release composition, which can effectively control the precise delivery of the blue copper peptide during use, significantly improve the hydration and elasticity of the skin, and prove its role in anti-aging use. The composition of the present invention is liquid at low temperature, and is converted into a gel semi-solid at body temperature to form a poloxamer gel grid, in which the blue copper peptide and other skin active peptides are embedded, thereby achieving slow and continuous drug release during use.

[0016] Since poloxamer is a thermosensitive polymer, it can form a gel at a concentration of 12.0% (mass fraction, the same below) to 30.0%. At the same time, poloxamer is a triblock copolymer of polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO), and its chemical formula is HO[CH2CH2O] x [CH2CH3]CH2O] y [CH2CH2O] x H, y>14. When poloxamer reaches the critical gelation temperature, the hydrophobic PPO block on the poloxamer chain in the aqueous solution is dehydrated, and PEO swells when it encounters water, thus forming spherical micelles with PPO as the hydrophobic core and PEO as the hydrophilic outer core. When the temperature rises, the entanglement and stacking of the micelles are intensified, resulting in sol-gel transition behavior. This is to improve the gelation concentration and drug sustained release performance of poloxamer at body temperature. According to the unique hydrophobic inner core-hydrophilic outer core structural characteristics of poloxamer, the present invention adds blue copper peptide, hydrophobic polypeptide and hydrophilic polypeptide at the same time, and the hydrophilic components acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine, snake venom tripeptide and blue copper peptide are distributed in the free solvent outside the micelle, while the hydrophobic component compounds palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4 are wrapped inside the micelle and stably embedded in the poloxamer gel grid, which protects and controls the release of blue copper peptide while also protecting and controlling the release of other polypeptide components.

[0017] In addition, the present invention realizes the meticulous regulation of the release rate of blue copper peptide and other skin active peptides by combining multiple active peptides and accurately controlling the concentration. In order to maximize the effect of blue copper peptide in skin regeneration and anti-aging, by adjusting the cross-linking density of the gel and the loading amount of blue copper peptide, the release rate of blue copper peptide is accurately controlled to ensure that it is continuously and stably released in the surface layer of the skin, maximizing its action time and effect. Among the added ingredients, acetyl hexapeptide-8 and snake venom tripeptide are instant anti-wrinkle ingredients, which need to reach a certain concentration to exert their optimal effect. Under the system of sustained and controlled release, with the continuous metabolism of the carrier material, the active ingredient is released with zero-order pharmacokinetics, ensuring that the active ingredient reaches an effective concentration. At the same time, the muscle is made to form muscle memory, thereby improving the wrinkle situation for a long time. Palmitoyl pentapeptide-4, as a signal peptide, can stimulate cells to synthesize collagen. Under the system of sustained and controlled release, signals are continuously released, so that the skin continuously synthesizes collagen.

[0018] The design of the sustained-release system of the present invention not only affects the dynamic process of drug release, but is also directly related to the biological activity and therapeutic effect of the components. In the application of blue copper peptide, the slow and continuous release can maintain the effective concentration of each component at the application site, promote the proliferation and differentiation of skin cells, accelerate wound healing, and improve the anti-aging effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the original mass spectrum of acetyl hexapeptide-8 in the example.

[0020] Figure 2 This is the original secondary mass spectrum of acetyl hexapeptide-8 in the example.

[0021] Figure 3 This is a standard curve drawn in the investigation of analytical methodology in the examples.

[0022] Figure 4 The facial skin changes of Wang X in a specific population after using the sample of the embodiment for four weeks

[0023] Figure 5 To investigate the facial skin changes of Zhu X in a specific population after using the sample of the embodiment for four weeks

[0024] Figure 6 The facial skin changes of the specific population after using the sample of the embodiment for four weeks

[0025] Figure 7 The facial skin changes of Wang X in a specific population after using the sample of the embodiment for four weeks

[0026] Figure 8 The facial skin changes of Li X in a specific population after using the sample of the embodiment for four weeks

[0027] Fig. 9 The facial skin changes of Liu X in a specific population after using the sample of the embodiment for four weeks

[0028] Fig.10 The facial skin changes of horse X in a specific population after using the sample of the embodiment for four weeks

[0029] Fig.11 To investigate the facial skin changes of Chen X in a specific population after using the sample of the embodiment for four weeks

[0030] Fig.12 The facial skin changes of Zhang X in a specific population after using the sample of the embodiment for four weeks

[0031] Fig.13 The facial skin changes of another Wang X in a specific population after using the sample of the embodiment for four weeks DETAILED DESCRIPTION

[0032] The present invention can be explained in detail by the following examples, and the purpose of disclosing the present invention is to protect all technical improvements within the scope of the present invention.

[0033] 1. The following examples are implemented for the high concentration blue copper peptide and active peptide sustained-release composition described in this patent

[0034] Embodiment 1:

[0035] A method for preparing a high-concentration blue copper peptide and active peptide sustained-release composition comprises the following steps: firstly, adding an appropriate amount of water to 1 kg of poloxamer, placing the mixture in a refrigerated environment at 5 degrees Celsius until the mixture is completely dissolved, thereby preparing a poloxamer stock solution with a mass fraction of 30%, dissolving 15 ppm of palmitoyl tetrapeptide-7 and 15 ppm of palmitoyl pentapeptide-4 in the poloxamer stock solution, thereby preparing a primary mixed solution; then, respectively adding and diluting water-soluble polypeptides to the primary mixed solution to the following concentrations: 100 ppm of acetyl hexapeptide-8, 100 ppm of acetyl tetrapeptide-5, 1100 ppm of decarboxylated carnosine, 250 ppm of snake venom-like tripeptide and 10000 ppm of blue copper peptide, and adding the mixture to the primary mixed solution in a refrigerated state at about 5 degrees Celsius, thereby preparing a sustained-release composition.

[0036] Embodiment 2-5

[0037] Examples 2-5 are prepared in the same manner as Example 1, except that the amounts of components added are different, as shown in Table 1.

[0038] Table 1 Components and their addition amounts in Examples 1-5

[0039] Components Example 1 Example 2 Example 3 Example 4 Example 5 Poloxamer stock solution 12.5％ 15％ 18％ 20％ 25％ Palmitoyl Tetrapeptide-7 15ppm 18ppm 16ppm 10ppm 20ppm Palmitoyl Pentapeptide-4 15ppm 10ppm 18ppm 20ppm 13ppm Acetyl Hexapeptide-8 100ppm 50ppm 150ppm 120ppm 80ppm Acetyl Tetrapeptide-5 100ppm 80ppm 120ppm 50ppm 150ppm Decarboxylated carnosine 1100ppm 1000ppm 1150ppm 1200ppm 1200ppm Snake venom tripeptide 250ppm 200ppm 280ppm 220ppm 300ppm Blue Copper Peptide 10000ppm 8000ppm 11000ppm 9000ppm 12000ppm

[0040] 2. Testing the recovery rate and sustained-release time of the samples in Examples 1-5:

[0041] Since poloxamer is a polymer, it is difficult to accurately quantify it. Blue copper peptide, fat-soluble peptide and water-soluble peptide are all skin active substances, and are all embedded in the micelle grid based on poloxamer thermosensitive gel. Although the component concentrations of each skin active substance are different, the release rates of different skin active substances are consistent. Therefore, acetyl hexapeptide-8, which is an easily detectable component in the example sample, is used to study the sustained and controlled release of the active substances in the example.

[0042] The accurate content was quantitatively analyzed by LC-MS coupling and MRM standard curve method. The original mass spectrum of acetyl hexapeptide-8 is shown in the attached Figure 1 As shown, the original secondary mass spectrum of acetyl hexapeptide-8 is attached Figure 2 shown.

[0043] Select [M+2H] of acetyl hexapeptide-8 2+ m / z446Da was selected as the parent ion, m / z102Da was selected as the quantitative ion, and m / z84Da was selected as the qualitative ion for MRM determination.

[0044] Instrument: WatersH-ClassUPLC, WatersQuattroMicroMS

[0045] Chromatographic column: Waters BEHAmide 1.7μm, 2.1mm*150mm

[0046] 1. Investigation of analytical methodology:

[0047] Standard curve drawing: Weigh 10 mg of acetyl hexapeptide-8, weigh accurately, and place in a 10 ml volumetric flask, use acetonitrile containing 0.05% formic acid: water = 1:1 as solvent to make up to 1 mg / ml stock solution 1. Take 0.25 ml of stock solution 1 and place it in a 25 ml volumetric flask, dilute with the above solution to obtain a stock solution 2 with a concentration of 10000 ng / ml. Dilute stock solution 2 with the above solvent to 10 ng, 50 ng, 100 ng, 150 ng, 200 ng, 500 ng / ml working solution, and measure 5 ul and inject into the liquid chromatography-mass spectrometer for LC-MSMS analysis.

[0048] Table 2 below is a quantitative analysis table, and the standard curve drawn is as shown in the attached Figure 3 shown.

[0049]

[0050]

[0051] 2. Determination of recovery rate:

[0052] Then the recovery rate was determined: a mouse was killed by cervical dissection, and two portions of muscle tissue with a mass of 1 g were dissected and cut out, and accurately weighed. 0.35 ml and 0.45 ml of the stock solution and 5 ml of the sample diluent of the embodiment were respectively measured for homogenization, and the volume was 10 ml. The above tissue homogenate was filtered using a 220 nm microporous filter membrane. 1 ml of the filtrate was taken and centrifuged at 16800 rpm for 30 min, the supernatant was taken and loaded into an automatic injection vial, and 5 ul was injected into the liquid-mass spectrometer for analysis.

[0053] The test results of Example 1 are shown in Table 3 below:

[0054] Addition amount ng / ml Actual measurement ng / ml Recovery rate % Recovery rate 1 350 345.6 98.74 Recovery rate 2 450 461.3 102.51

[0055] Using the above test method, the results show that the measured concentrations of Examples 1-5 with 0.35 ml of stock solution added have recoveries in the range of 90%-108%, indicating a good recovery rate.

[0056] 3. Determination of sustained-release time:

[0057] The samples in Examples 1-5 were subjected to a controlled release time test:

[0058] The test method is: the same determination method is used to determine the sustained-release time: 7 mice are taken respectively, and 0.1 ml of the sample in Example 1 is injected respectively. One mouse is killed by cervical dislocation every day for dissection, and 1 g of tissue around the injection site is taken, accurately weighed, and stored in a -80°C refrigerator. The animal tissue is added to 5 ml of sample diluent for homogenization, and the volume is 10 ml. The above tissue homogenate is filtered using a 220 nm microporous filter membrane. Take 1 ml of the filtrate, centrifuge at 16800 rpm for 30 min, take the supernatant and put it into an automatic sampling vial, and take 5 ul to inject into the liquid-mass spectrometer for analysis.

[0059] Table 4 shows the results of the sample concentration test in mice for seven days in Example 1.

[0060] serial number Dilution multiple Determination of concentration ng / ml Actual concentration ng / ml 1 30 230.5 6915 2 30 98.8 2964 3 10 93.7 937 4 10 68.7 687 5 10 33.7 337 6 10 22.2 222 7 10 10.9 109

[0061] Using the above test method, Table 5 shows the test results of the acetyl hexapeptide-8 sample concentration in mice in each embodiment on the seventh day.

[0062] sample Actual measurement ng / ml Example 1 109 Example 2 53 Example 3 114 Example 4 96 Example 5 65

[0063] The results showed that after seven days, the samples in Examples 1-5 could still be successfully detected in mice, which proved that the sustained-release time of the samples in Examples 1-5 exceeded one week.

[0064] 3. Testing the effects of the samples in Examples 1-5 on specific groups of people

[0065] 1. The samples in Examples 1-5 were used on a specific group of people, and a facial roughness improvement test was performed using a VISIA skin testing instrument within one month, wherein a higher roughness value represents smoother skin:

[0066] Table 6 shows the surface roughness changes of the samples after one month of use.

[0067] Example Name gender age Roughness Week 1 Week 2 Week 3 Week 4 1 Zhang X male 30 64 64 68 71 75 1 Jiang X male 30 53 56 61 64 68 1 Reckless female 30 59 60 61 64 67 1 Hao X male 31 48 48 50 53 56 1 Zhu X female 31 62 62 64 67 70 1 Liu X male 34 56 57 59 64 67 2 Wei X female 34 56 56 59 62 64 2 Zhou X male 35 58 60 62 65 67 2 Dong X female 35 53 55 58 62 63 2 Shen X male 36 49 52 53 56 57 2 YuX female 36 55 55 59 62 64 2 Wang X female 39 51 53 56 58 62 3 Hu X male 40 54 55 57 60 62 3 Wear X female 40 47 50 51 54 55 3 Zheng X male 41 52 55 58 61 63 3 SuX female 41 48 48 49 50 50 3 Hao X female 45 46 48 49 51 53 3 Song X female 47 42 44 45 47 50 4 Lu X female 47 44 48 50 53 55 4 White X male 49 40 43 45 46 50 4 Chen X female 50 36 40 42 45 47 4 Shen X female 50 38 40 41 42 46 4 Ginger X female 50 35 39 40 43 45 4 Xu X female 52 35 37 38 42 46 5 Song X female 53 30 33 34 37 41 5 Hu X female 54 32 36 38 41 44 5 Flat X female 54 37 37 39 40 42 5 Luo X male 55 32 34 35 36 39 5 Zheng X female 55 31 33 34 36 38 5 Zeng X female 55 34 36 38 40 42

[0068] 2. The samples in the embodiment are used on a specific group of people, and a facial texture improvement test is performed within one month, wherein a higher texture value represents less skin texture and smoother skin:

[0069] Table 7 shows the facial texture changes of the samples after one month of use

[0070]

[0071]

[0072] From the experimental results in Table 6 and Table 7, it can be seen that the samples in the examples have the effect of reducing wrinkles and skin roughness to a certain extent. Figure 4 -Attached Fig.13 As shown, the left side of the photo is before use, and the right side is after use.

[0073] The above experimental results show that the high-concentration blue copper peptide and active peptide sustained-release composition can stably release blue copper peptide and other skin active substances at body temperature, and the duration exceeds the traditional delivery system. The use of the composition to treat the facial roughness and texture of human skin tissue has a unique and significant improvement. In addition, the application of the composition significantly improves the hydration and elasticity of the skin, proving its potential in anti-aging treatment.

[0074] Future research of this study will further explore the application of this composite system in other biomedical fields, such as controlled release systems, biosensors, and cell culture carriers, which is expected to have a broader impact on the fields of biomedical engineering and regenerative medicine.

Claims

1. A high-concentration blue copper peptide and active peptide sustained-release composition, characterized in that: Including poloxamer, blue copper peptide, fat-soluble peptide and water-soluble peptide.

2. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: Said include: The fat-soluble polypeptides include palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4.

3. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: The water-soluble polypeptides include: acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine, and snake venom-like tripeptide.

4. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: The mass fraction of the poloxamer is 12-25%.

5. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: The mass concentration of the blue copper peptide is 8000-12000 ppm.

6. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: The mass concentration of the acetyl hexapeptide-8 is 50-150 ppm, the mass concentration of the acetyl tetrapeptide-5 is 50-150 ppm, the mass concentration of the decarboxylated carnosine is 1000-1200 ppm, the mass concentration of the snake venom tripeptide is 200-300 ppm, the mass concentration of the palmitoyl tetrapeptide-7 is 10-20 ppm; and the mass concentration of the palmitoyl pentapeptide-4 is 10-20 ppm.

7. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 3, characterized in that: The mass fraction of the poloxamer is 12.5%.

8. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 1, characterized in that: The palmitoyl pentapeptide-4 can also be replaced by one or more of palmitoyl dipeptide-7, tripeptide-3 or acetyl tetrapeptide-11.

9. The high concentration blue copper peptide and active peptide sustained-release composition as claimed in claim 5, characterized in that: The mass concentration of the blue copper peptide is 10000ppm, the mass concentration of acetyl hexapeptide-8 is 100ppm, the mass concentration of acetyl tetrapeptide-5 is 100ppm, the mass concentration of decarboxylated carnosine is 1100ppm, the mass concentration of snake venom tripeptide is 250ppm, the mass concentration of palmitoyl tetrapeptide-7 is 15ppm and the mass concentration of palmitoyl pentapeptide-4 is 15ppm.

10. A method for preparing a high concentration blue copper peptide and active peptide sustained-release composition according to claims 1 to 9, characterized in that: The preparation steps are as follows: weighing poloxamer with a mass fraction of 12-25%, adding ultrapure water, placing in a refrigerated state until completely dissolved, preparing a 30% poloxamer stock solution, then dissolving fat-soluble polypeptides palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4 in the poloxamer stock solution, and diluting to the mass concentration to prepare a primary mixed solution; then taking another aqueous phase to dissolve water-soluble polypeptides acetyl hexapeptide-8, acetyl tetrapeptide-5, decarboxylated carnosine, snake venom tripeptide and blue copper peptide, and adding them to the primary mixed solution in a refrigerated state at about 5 degrees Celsius to prepare a sustained-release composition.

Images